SK

Sungwuk Kim

North America, Texas, United States, Houston

Description

Sung-wuk Kim has served as Chairman of the Board of Directors and Chief Executive Officer (CEO) since the founding of ImmunoMet Therapeutics...

Investor Profile

Sungwuk Kim has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biopharma, Biotechnology, Health Care.

Stage Focus

  • Series B (100%)

Country Focus

  • United States (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Health Care
  • Oncology
  • Pharmaceutical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Sungwuk Kim frequently co-invest with?

SL Investment
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Mirae Asset Venture Investment
Asia, Kyonggi-do, South Korea, Seongnam
Co-Investments: 1
GT
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
I
North America, Washington, United States, Kirkland
Co-Investments: 1
NHN Investment
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1

What are some of recent deals done by Sungwuk Kim?

ImmunoMet Therapeutics

Houston, Texas, United States

ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients.

BiopharmaBiotechnologyHealth CareOncologyPharmaceuticalTherapeutics
Series BMar 7, 2017
Amount Raised: $5,000,000